Topics
ArticleFast-tracking AI-designed binders with cell-free expression and SPR
AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
ArticleSample collection: the overlooked key to genomic study success
As genomic studies become larger and more diverse, sample collection can make or break their success. Discover why collection strategy matters for recruitment, scale and data quality.
ArticleWhy more ribosomes can mean less protein in mRNA therapeutics
What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation speed could matter for the design of mRNA medicines.
ArticleWhy depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
WebinarWhat it takes to automate high-content imaging at scale
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
WebinarThe truth about AI in drug discovery: what the experts really think
AI is transforming drug discovery - but beyond the hype, what’s actually delivering results? In this expert-led webinar, industry leaders explore where AI is accelerating target identification, molecule design and hit discovery, while also confronting the real-world challenges of data quality, validation and adoption. Discover what’s working today, what still ...
WebinarCan One Peptide Change Pain Research? Meet the Tool Transforming Drug Discovery
Discover how a new peptide tool, WRPRFa, is helping researchers better understand pain pathways and accelerate the search for next-generation analgesics.
WebinarOvercoming Affinity and Expression Bottlenecks in TCR Discovery
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
- Article
Why depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
ArticleHow rare genetic variants could uncover new drug targets
What if extreme levels of common traits have a different genetic basis? New research suggests rare, large-effect variants could help explain the extremes and identify potential drug targets.
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
ArticleFibroblast barrier linked to immunotherapy resistance in colorectal cancer
Why do some colorectal cancers resist immunotherapy? Analysis of patient tumour samples has identified a population of fibroblasts that could help explain treatment resistance.
- Article
Fast-tracking AI-designed binders with cell-free expression and SPR
AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
- Article
Why more ribosomes can mean less protein in mRNA therapeutics
What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation speed could matter for the design of mRNA medicines.
ArticleWhat makes a human biospecimen fit for purpose in drug discovery
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample itself. We explore the factors that determine how much researchers can learn from them.
- Article
Why depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
- Article
Fast-tracking AI-designed binders with cell-free expression and SPR
AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
- Article
Sample collection: the overlooked key to genomic study success
As genomic studies become larger and more diverse, sample collection can make or break their success. Discover why collection strategy matters for recruitment, scale and data quality.
- Article
Why more ribosomes can mean less protein in mRNA therapeutics
What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation speed could matter for the design of mRNA medicines.
- Article
Why depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
- Article
Fast-tracking AI-designed binders with cell-free expression and SPR
AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
- Article
Sample collection: the overlooked key to genomic study success
As genomic studies become larger and more diverse, sample collection can make or break their success. Discover why collection strategy matters for recruitment, scale and data quality.
- Article
Why more ribosomes can mean less protein in mRNA therapeutics
What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation speed could matter for the design of mRNA medicines.
- Article
What makes a human biospecimen fit for purpose in drug discovery
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample itself. We explore the factors that determine how much researchers can learn from them.
ArticleDrug development has changed. Bioanalysis is changing with it
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
ReportAI in Drug Discovery: Progress, Limits and What Comes Next
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
ArticleWhy targeted therapies are exposing the limits of animal models – and what comes next
Traditional preclinical models are struggling to keep pace with a new generation of targeted therapies. As regulators embrace new approach methodologies (NAMs), vascularised tissue platforms are offering a more human-relevant approach to predicting drug efficacy and safety.
ArticleWomen in STEM: resilience and leadership in rare disease research
Rare neurological diseases remain one of the most challenging areas in drug discovery, with many patients still lacking treatment options. Dr Nitza Thomasson discusses returning to Servier to lead its rare neurology therapeutic area and explains why resilience, curiosity and persistence are essential for those looking to build a meaningful career in STEM.